Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

The Associated Press August 10, 2010, 4:50PM ET

Noven Therapeutics to acquire rights to Daytrana

Noven Pharmaceuticals Inc. said Tuesday that it has reached an agreement with Shire PLC to market and sell a patch for Attention Deficit and Hyperactivity Disorder.

Noven did not disclose how much it paid for the global rights to Daytrana.

The drug was developed and manufactured by Noven but was originally licensed to Shire in 2003 and launched in the U.S. in 2006.

Shares of Shire rose 77 cents to close Tuesday at $71.18.

BW Mall - Sponsored Links

Buy a link now!